rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IRON
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Disc Medicine at Jefferies Global Healthcare Conference: bitopertin rebound
      14h agoInvesting.comIRONJEF
      Disc Medicine at UBS biopharma conference: pipeline gains momentum
      Nov 17Investing.comIRONUBS
      Disc Medicine at Guggenheim conference: cash-rich push into launch phase
      Nov 9Investing.comIRON
      Guggenheim initiates Disc Medicine stock coverage with buy rating
      Nov 9Investing.comIRON
      Disc Medicine earnings on deck after Phase 3 bitopertin win
      Nov 4Investing.comIRON
      iShares Russell 2000 (IWM) Buys $8.5 Million More Disc Medicine on Friday
      Oct 27Yahoo FinanceIRON
      Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
      Oct 22Yahoo FinanceIRON
      Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP - Slideshow
      Oct 21Seeking AlphaIRON
      Disc Medicine director Bitterman sells $3.35m in shares
      Oct 21Investing.comIRON
      Jefferies raises Disc Medicine stock price target on drug opportunity
      Oct 21Investing.comIRON
      Exclusive BAC Article: Disc Medicine; Positive Ph APOLLO Study Bitopertin EPP, NDA Resubmission Possible End Of 2026, FDA Feedback Selcodebart Same Time, And Catalysts (NASDAQ:IRON)
      Oct 21Seeking AlphaIRON
      Why is Disc Medicine stock sliding today?
      Oct 21Investing.comIRON
      Disc Medicine Prices $450 Million Upsized Public Offering
      Oct 21Yahoo FinanceIRON
      Disc Medicine prices $450 million stock offering at $75/share
      Oct 21Investing.comIRON
      Disc Medicine stock price target raised to $115 by Truist on drug outlook
      Oct 20Investing.comIRONTFC
      A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
      Oct 20Yahoo FinanceIRON
      Cantor Fitzgerald raises Disc Medicine stock price target on trial data
      Oct 20Investing.comIRON
      Disc Medicine: APOLLO Changes The Story, But How Much Upside Remains (NASDAQ:IRON)

      Disc Medicine (IRON) posted strong APOLLO Phase 3 bitopertin results in EPP/XLP and plans an end-2026 NDA resubmission.

      Oct 20Seeking AlphaIRON
      Wells Fargo raises Disc Medicine stock price target on competitive profile
      Oct 20Investing.comIRON
      Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan
      Oct 20Yahoo FinanceIRON
      AMZN, CLF, IRON, SLN, EYPT: 5 Trending Stocks Today - Amazon.com (NASDAQ:AMZN)

      Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.

      Oct 20BenzingaEYPTIRONSLNCLF
      Disc Medicine Launches $350 Million Securities Offering
      Oct 19Yahoo FinanceIRON
      Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In Focus
      Oct 19Yahoo FinanceIRON
      Disc Medicine launches $350 million stock offering
      Oct 19Investing.comIRON
      What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?
      Oct 19Yahoo FinanceIRON
      Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study - Disc

      Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and secondary endpoints. NDA resubmission planned.

      Oct 19BenzingaIRON
      Disc’s once-spurned rare disease drug to get a second chance at approval
      Oct 19Yahoo FinanceIRON
      Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
      Oct 19Yahoo FinanceIRON
      Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes

      Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.

      Oct 19Barron'sIRON
      BMO raises Disc Medicine stock price target on positive trial data
      Oct 19Investing.comIRON
      Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
      Oct 19Yahoo FinanceIRON
      Wedbush Adjusts Price Target on Disc Medicine to $110 From $100, Maintains Outperform Rating
      Oct 19Yahoo FinanceIRON
      Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday - Silence T

      U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.

      Oct 19BenzingaIRONSLN
      Disc Medicine Shares Rise 60% After Phase 3 Bitopertin Trial Meets Primary and Secondary Endpoints
      Oct 19Yahoo FinanceIRON
      12 Health Care Stocks Moving In Monday's Pre-Market Session - Disc Medicine (NASDAQ:IRON), DataMEDS AI (N

      Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved upwards by

      Oct 19BenzingaIRON
      Why is Disc Medicine stock surging today?
      Oct 19Investing.comIRON
      Disc Medicine surge 60% on positive Phase 3 trial for rare sunlight disorder
      Oct 19Investing.comIRON
      Disc Medicine surges on late-stage trial win for lead asset developed with Roche
      Oct 19Seeking AlphaIRON
      Disc Medicine reports positive phase 3 trial results for EPP drug
      Oct 19Investing.comIRON
      Disc Medicine rallies 32% as investors await bitopertin trial results (IRON:NASDAQ)
      Oct 19Seeking AlphaIRON
      Disc Medicine to present Phase 3 trial results for bitopertin
      Oct 18Investing.comIRON
      Disc Medicine (IRON) Stock Still Looks Pricey As Book Value Lags Expectations
      Oct 18Yahoo FinanceIRON
      Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Disc Medicine (IRON)

      Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailHRMYIRON
      Disc Medicine: Second To Market, Priced Like It's First (NASDAQ:IRON)

      Disc Medicine is a high-risk sell as bitopertin's steep valuation ignores prior FDA pushback and looming market competition. Learn more about IRON stock here.

      Oct 13Seeking AlphaIRON
      10 Health Care Stocks With Whale Alerts In Today’s Session - Moderna (NASDAQ:MRNA), Disc Medicine (NASDAQ

      This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

      Oct 12BenzingaIRONMRNA
      Disc Medicine options activity points to Phase 3 bitopertin catalyst bet
      Sep 30Investing.comIRON
      Disc Medicine at Morgan Stanley conference: pipeline nears key tests
      Sep 14Investing.comIRONMS
      Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
      Sep 10BenzingaIRON
      Disc Medicine at Wells Fargo conference: two drug bets near key tests
      Sep 10Investing.comIRONWFC
      H.C. Wainwright reiterates Disc Medicine stock rating on trial data
      Sep 10Investing.comIRON

      This is the newest page. Registered accounts read further back.